Table 1. Morphological Data.
| Group | BW (g) | HW (mg) | HW/BW (mg/g) |
|---|---|---|---|
| Control | 28.3 ± 0.4 | 131.3 ± 1.7* | 4.65 ± 0.05* |
| T4 | 28.9 ± 0.5 | 173.1 ± 2.8 | 6.02 ± 0.07 |
| DMSO + T4 | 29.3 ± 0.7 | 179.4 ± 5.7 | 6.13 ± 0.15 |
| Sorafenib + T4 | 25.6 ± 1.0* | 163.7 ± 5.5 | 6.45 ± 0.17* |
| TadalafilIP + T4 | 28.3 ± 0.5 | 176.1 ± 3.5 | 6.22 ± 0.08 |
| TadalafilOr + T4 | 29.8 ± 0.8 | 174.2 ± 6.0 | 5.84 ± 0.09 |
| CMC + T4 | 28.6 ± 0.4 | 171.5 ± 6.5 | 6.01 ± 0.20 |
| MacitentanLD + T4 | 27.1 ± 0.7 | 166.7 ± 3.4 | 6.16 ± 0.10 |
| MacitentanHD + T4 | 28.8 ± 0.4 | 172.0 ± 2.2 | 5.98 ± 0.07 |
BW: body weight, HW: heart weight, Control; n = 21, Thyroxin (T4); n = 33, Dimethyl sulfoxide (DMSO); N = 14, Sorafenib; n = 13, TadalafilIP (intraperitoneal, 1 mg/kg); n = 21, TadalafilOr (oral, 4 mg/kg); n = 8, carboxymethylcellulose (CMC); n = 10, MacitentanLD (Low dose: 30 mg/kg); n = 10, MacitentanHD (High dose: 100 mg/kg); n = 8.
*: indicates a significant change as revealed by one-way ANOVA followed by Dunnett Multiple Comparisons post-hoc test, comparing all groups to T4.